Mike Moore sits down with Jae Bang, Founder & CEO of Future Cardia, a company that is redesigning how Heart Failure & Arrhythmia patients will be monitored in the future. Their subcutaneous implant offers simplicity, accuracy, and high compliance for long-term monitoring, with existing reimbursement.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/

Episode 31 may be our most interesting interview yet! In this session, host Mike Moore sits down with Rohan Kalahasty (Co-Founder & CEO) & Sai Mattapalli (Co-Founder & COO/CFO) of Vytal.ai. Using state of the art AI systems and revolutionary eye gaze tracking technology, Vytal allows for 30-second brain health evaluations from the comfort of your own home. Their story is a great one, and even more unique given that these two Co-Founders are still seniors in high school!Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/

Host Mike Moore interviews Co-Founder & Chief Medical Officer, Dr. Randy Moore of ViTAA Medical. ViTAA's AI-backed SaMD offers precision, personalized medicine to non-invasively map the strength and weakness of abdominal aortic aneurysms (AAA). ViTAA’s RAW™ (Regional Areas of Weakness) Map technology can analyze the deformation of the aorta wall using images captured throughout the cardiac cycle.Then, by incorporating critical simulation data on blood flow and the location and size of clots (ILT or intraluminal thrombus) within the aneurysm, ViTAA’s algorithms compute and generate detailed vulnerability maps of the abdominal aortic aneurysm.The technology is available as part of the ViTAA Registry which has been launched in 8 North American sites. Further access to the technology will also be possible through ViTAA’s Research Use Only Program, which was initiated in late 2022.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/

Host Mike Moore & Renee Ryan discuss Cala Health's kIQ™ wearable technology. kIQ™ is the only FDA-cleared, wearable device that delivers effective therapy for action hand tremors in people with essential tremors and Parkinson’s disease.kIQ, pronounced “kick,” stands for Kinetic [movement] + IQ [smart]Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/

Host Mike Moore interviews Co-Founder & CEO of Nutromics, Peter Vranes. Nutromics is developing the world’s first continuous, real-time, wearable diagnostic monitoring device that utilizes multiple DNA-based sensors with microneedles. It has been described as a “Lab-On-A-Patch”, where the number of diagnostics it can monitor is limited solely by the number of microneedles it can fit on the patch.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/

In this week’s episode, host Mike Moore speaks with Lloyd Diamond, CEO Pixium Vision, about their technology that focuses on bionic vision for those who have lost their sight.Pixium Vision utilizes the latest advancements in visual processing, micro-electronics, optoelectronics, neurobiology, and intelligent software algorithms to create Bionic Vision Systems. By leveraging their expertise in machine brain interface and artificial intelligence, Pixium Vision aims to develop these systems to address severe vision loss and enhance the autonomy, movement, and overall well-being of individuals affected by retinal degenerative diseases.Today, Mike and Lloyd discuss Pixium Vision's bionic vision technology, which aims to restore sight for visually impaired individuals. Lloyd explains the company's background, their first-generation technology called Iris, and their second-generation technology called Prima. He demonstrates how the technology allows patients to read a weather forecast and identifies basic features using the glasses. They also discuss the surgical process, the uniqueness of Pixium Vision's technology, and their regulatory status.Notable Quotes“Basically, we're targeting dry AMD. Dry AMD is a disease where the photoreceptor cells no longer function, what we do is we create a small incision in the retina, and we inject our premier implant in the subretinal space, we apply gas or oil to reattach the retina.”- Lloyd (05:23)“I think as humans inherent in the cellular level of the retina, we can see red, green, and blue, but then everything else is learned. When you're a kid, the teacher says, Oh, this is yellow. And now you learn that that's yellow. So inherent in the retina is only red, green, and blue.” - Lloyd (12:22) In This Episode(01:59) The origin story of Pixium Vision(05:11) The technology behind Pixium Vision's product(10:30) How a legally blind patient can read a weather forecast using bionic vision technology(12:20) The ability to enhance contrast and identify facial traits(14:53) The target indications and market potential(21:27) Detaching the retina and surgical training(23:10) Advancements in implant technology(26:59) Regulatory progress and commercialization plans(32:26) The company's investment and future plans(33:26) Clarity on the investment process(33:48) Classification of investmentsOur GuestLloyd Diamond is the CEO of Pixium Vision. He has 25 years of experience in medtech, leading disruptive technology commercialization in life sciences. He successfully penetrated markets in Europe and the US, including a NASDAQ IPO. He holds dual degrees in Biochemistry and Marketing and an MBA.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeLloyd Diamondhttps://www.pixium-vision.com/https://www.linkedin.com/in/lloyd-diamond

In this week’s episode, host Mike Moore speaks with Steven Scott, CEO and President of VitalTech, about how their cloud-based platform revolutionizes chronic care management and care coordination.VitalTech's platform is a SaaS-based solution that utilizes cloud technology to allow patients to access the program through an application on their device. By aggregating biometric data from various devices such as wearables and peripherals via Bluetooth, the platform can provide real-time feedback and trend analysis, allowing for early intervention and prevention of health issues. It also includes patient-reported outcomes, medication adherence, and nutritional modules, providing a holistic approach to care coordination.Today, Mike and Steven discuss the benefits of VitalTech's solution for patients and providers, and how it's changing the digital health space. If you're tired of constantly going to the emergency room for chronic care management, VitalTech's solution might be the answer.Notable Quotes“We participate in the digital market and within that, it's the virtual care realm that we're really servicing and as services are getting pushed more and more to the home. And people are looking for early indicators of what's going on. And as people are aging, and the age wave hits, the number of chronic cases that come up with chronic disease states that come up.” - Steven (03:46) "There are ways to interact with the patient beyond just the biometric measures that are coming in. So it's more of we try to say a holistic approach to how the information is done by the care provider or the care coordinator, who can then help you action that information. Because a lot of times you can't see the forest but you can see the trees. – Steven (17:34) In This Episode(01:27) The origin story of VitalTech (03:44) The problem VitalTech is trying to solve and the different disease states they are addressing(09:34) How VitalTech's SaaS-based platform works(14:37) How the introduction of 5G has changed the game in the digital health space(21:33) Power of the VitalTech platform and the importance of tracking patient information over time(26:11) Accountability and intervention: how the VitalTech platform creates accountability for patients and enables doctors to intervene before a patient's condition worsens(29:15) Benefits of VitalTech's solution(35:31) How physicians can capture reimbursement for remote patient monitoring and care coordination through CPT codes(38:22) The transition of care from an acute care setting to home and the hot space of VitalTech's solution for chronic care management.(39:31) Commercial availability of VitalTech's solution(40:31) How multiple physicians can engage and access the platform through video conferencing or exchanging information and data through their EMR.Our GuestsSteven Scott is the President and CEO of VitalTech, a company specializing in Medical Devices and Equipment. VitalTech was established in 2018 and has approximately 25 staff members. Steven is a member of the Executive team within the C-Suite Department, holding a high-level management position at the C-Level. Presently, he is located in Plano, United States.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeScott Stevenhttps://vitaltech.com/

In this week’s episode, host Mike Moore talks with Meet Vora and Rajatesh Gudibande, co-founders of GraphWear Technologies Inc., about their innovative creation—a needle-free continuous glucose monitoring device aimed at enhancing the management of diabetes that is poised to revolutionize both the technology and healthcare sectors.GraphWear Technologies Inc. is a San Francisco-based technology company that was founded in 2015 and revolutionizes chronic condition management with needle-free, continuous glucose monitoring technology. Their mission is global accessibility, mitigating pain and costs associated with traditional treatments. Working tirelessly to make wearable devices available to all in need.Today, Mike, Meet, and Rajatesh talk about the creation of a glucose monitoring device without needles. They discuss the size of the diabetes market and the challenges faced while developing the technology. They also explore how Apple entering the market could have an impact, and why it's important to have a strong company culture.Notable Quotes“Insulin has been the biggest contributor towards lack of management because insulin is one molecule which can control and that has been misused, I would say, a lot by different companies, of course, to make profits which I don't blame them for, but when it was invented, it was made towards the time it was signed up for a dollar, almost like the people's use and then unfortunately, people don't have access to that molecule that was so cheap to make.” - Rajatesh (08:38) “A company as big as Apple if they are making strides in this industry, it's only going to help everyone because they're going to educate everyone on the importance of why glucose monitoring is important and we in this community, I don't think any one of us look at that as a threat, but rather we are also having to help the diabetic community.” - Meet (15:03) In This Episode(01:25) The origin story: personal experiences that led to the creation of GraphWear(06:50) How type 2 diabetes patients develop a resistance to insulin(07:57) The diabetes epidemic in the market and insulin access issues(09:57) Introduction to the needle-free continuous glucose monitoring technology(11:23) Challenges of needle-free glucose monitoring(15:01) The impact of Apple's entry into the digital health space(15:41) Apple's long-standing development of non-invasive glucose monitoring technology(17:32) GraphWear's specificity factor in glucose monitoring(18:33) The current stage of development and regulatory process for the needle-free continuous glucose monitoring technology(20:30) Opportunity in elite performance management(21:22) GraphWear's culture and first principles of thinking(25:44) Importance of self-policing in high-performing teamsOur GuestsRajatesh Gudibande, Co-Founder and CEO of GraphWear, holds a Bachelor's in electrical and electronics engineering from Jawaharlal Nehru Technological University and a Master's in nanotechnology from the University of Pennsylvania. He pioneers non-invasive glucose monitoring, championing accessible healthcare solutions with $20.5M in funding.Meet Vora is the Director of Operations & Founding member at GraphWear Technologies Inc. With extensive work experience since 2012, he has excelled in various roles, including Chemistry Lab Intern, Graduate Advisor, Co-Founder & CTO, and Regulatory Affairs Analyst. Meet holds a B. Tech. in Chemical Engineering, an MSE in Nanotechnology, and multiple entrepreneurship certificates.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeMeet Vorahttps://www.graphwear.co/https://www.linkedin.com/in/meetvora/ Rajatesh Gudibandehttps://www.graphwear.co/https://www.linkedin.com/in/rajatesh-gudibande-07108423/

In this week’s episode, host Mike Moore talks with Bill George, former chairman and CEO of Medtronic, about his experience leading Medtronic and his thoughts on leadership in today's business world.Medtronic is a renowned company specializing in the development and production of advanced medical devices and therapies aimed at addressing over 30 chronic conditions. Their groundbreaking innovations cover a wide range of ailments, such as heart failure, Parkinson's disease, urinary incontinence, Down syndrome, obesity, chronic pain, spinal disorders, and diabetes. With a strong focus on improving patients' lives, Medtronic consistently pushes the boundaries of medical technology to provide effective solutions for these challenging health conditions.Today, Mike and Bill discuss the challenges of leading in a stakeholder model, the trend of layoffs in companies, and the impact on company culture and talent recruitment. They also touch on the topics of talent recruitment and leadership development in the tech industry, digital health, and the pressure on CEOs to weigh in on social issues.Notable Quotes“We were quite conservative in hiring. So we were kind of slow to hire, slow to fire, and tried never to lay off. And I had a policy of never, no matter what happened, laying off R&D people. I mean, if people weren't performing, they could leave. But we never had a layoff. And we never had a layoff among our sales people either. – Bill (06:08) “As a CEO, you change your position on something, that's when the activists come after you, that's when the politicians come after you. So if you stand for something, Medtronic stands for helping patients. And so anyone wants to take Medtronic on, that's fine. We're going to stand forever to help patients. – Bill (28:18)In This Episode(03:28) Challenges of leading in today's business world and the need to stay true to mission and values(05:17) The trend of layoffs in companies and Bill’s approach to it when leading at Medtronic(10:04) Underestimation of the Medtech field(11:12) The biggest challenge digital health leaders are facing today and how to overcome it.(14:33) Advice for early-stage companies looking to recruit(16:13) The importance of having a mission beyond just making money (18:42) Advice for first-time founders in developing leadership skills and attracting/leading employees.(23:54) The hybrid work model and the importance of personal contact in the workplace.(26:09) Advice for CEOs weighing in on social issues(30:04) The genesis of Medtronic's four-for-one stock option plan and how it was a valuable tool for recruiting and retention.(32:30) Challenges of leadership and layoffs Our GuestBill George is an executive fellow at Harvard Business School and former CEO of Medtronic. He has served on the boards of Goldman Sachs, ExxonMobil, Novartis, Target, and the Mayo Clinic. Bill is a prolific author of leadership books, including "True North" and "Authentic Leadership," and is renowned for his expertise in leadership development.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeBill Georgehttps://www.linkedin.com/in/williamwgeorge/https://billgeorge.org/Mentioned booksTrue North: Discover Your Authentic Leadership - https://www.amazon.com/True-North-Discover-Authentic-Leadership/product-reviews/B000XJNDVGTrue North: Leading Authentically in Today's Workplace, Emerging Leader Edition - https://www.amazon.com/True-North-Authentically-Workplace-Emerging/dp/1119886104

In this week’s episode, host Mike Moore talks with Andrew Malcolmson and Ashwin Belle, CEO and co-founder, and Chief Analytics Officer of Fifth Eye respectively. Fifth Eye has developed an AI-powered software as a medical device platform called AHI that measures heart rate variability to detect and predict hemodynamic instability.Today, Mike, Andrew, and Ashwin discuss the science behind the AHI platform, its potential applications, and the regulatory process involved in bringing it to market. They also discuss the benefits of AHI in providing early insight into a patient's condition, allowing for more proactive interventions and potentially avoiding costly adverse events. The conversation also covers the economic benefits of AHI, including cost avoidance, better resource allocation, and avoiding unreimbursed hospital-acquired events.Notable Quotes“Having a cloud-based solution where we can get the information processing to give you results in real-time, but we also have the ability to push it back down so you can see it and, you know, react to it on whatever screen you're already looking at, whether it's your, you know, central research station or in the ICU just in the EMR, if that's the place you want it or if you want it at the patient's bedside, that's achievable as well.” – Andrew (27:56)“I think from the team's strengths perspective, we really pride ourselves on the combination of signal processing and machine learning, where most technologies tend to do a lot and they explain a lot about the machine learning because they're using flight data that comes in from each of the structured systems they do using dynamic data by using data that comes in continuously at a high speed.” – Ashwin (34:38)In This Episode(02:08) Comparison of the AHI platform to pulse oximetry(05:39) Potential applications of the AHI platform (07:59) The science and breakthrough behind the AHI platform(09:29) The experimental dataset captured by the Department of Defense to simulate hypovolemia(14:36) How Fifth Eye's platform enhances patient monitoring, aiding clinical decision-making protocols.(16:26) Real-time detection and prediction(20:05) Economic value of AHI to hospitals (22:35) Differences from other early detection systems(24:30) How Fifth Eye's AI-powered software complements existing early detection  systems(25:15) Fifth Eye's solution for processing live streaming data challenges.(29:39) Feedback from early adopters(34:02) Fifth Eye product roadmap(36:36) Biggest opportunities and challenges for AHI moving forward(39:48) Fifth Eye’s corporate culture and its importance in the current work environmentOur GuestsAshwin Belle is a highly experienced professional with over a decade of leadership in healthcare research and development. His expertise spans ideation, R&D, design, productization, clinical trials, licensing, FDA regulation, go-to-market strategy, and commercialization, all aimed at improving patient care and saving lives.With over 20 years in MedTech, Andrew Malcolmson boasts extensive expertise in both Medical Equipment and Medical Software. His background spans R&D, Sales & Marketing, and Strategic Business Development in Medical Device companies both large and small, and he has been leading the application of data science to solve today’s clinical challenges since starting one of the first Remote Monitoring & Clinical Decision Support software platforms at Covidien (Now Medtronic) in 2011.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeAndrew Malcolmson  https://www.linkedin.com/in/andrew-malcolmson-7415972/Ashwin Bellehttps://www.linkedin.com/in/ashwinbelle/Fifth Eyehttps://fiftheye.com/

This week on The Bleeding Edge of Digital Health, host Mike Moore speaks with entrepreneur, scientist, and co-founder of Hexoskin, Pierre-Alexander Fournier. Pierre’s company specializes in developing wearable health sensors and smart clothing. He is passionate about creating smart, innovative solutions to improve care for patients with rare and chronic diseases. Mike and Pierre talk about how his latest tech garment is being utilized in health care today, how it is benefiting not just the patient but the physician as well, and more importantly, the future products and garments in Hexoskin’s pipeline that will pave the way for further innovation and change the way we take care of our health, and the health of the ones we care about. Be sure to listen to the entire session.Notable Quotes“So, we're working on different garments. We do have another product that has more sensors called the Astro skin that is being used in research, and that's the product that is being used in the space station right now for different research projects in microgravity. It's also the Astro skin is also what Chris Hemsworth is wearing in Limitless.” – Pierre-Alexander (29:10)“The research groups we're working with have built the largest database of vital signs, data about that specific health condition that exists. So, there are a lot of things that will come out of it. And as I said earlier, we're not just building a product for single use. Eventually, we're going to add blocks to that platform so that it can be used for several types of disease, and it's going to become a great bundle for people with comorbidities.” – Pierre-Alexander (30:59)In This Episode(01:46) The origin story of Hexoskin. (08:58) On being early for health care and the system catching up with them.(11:20) The tech behind the garments and the biomarkers they measure.(13:55) Why did they go with the shirt form factor?(16:04) The use cases for these garments in health care today.(20:49) The transition of care from the hospital to the home.(22:20) The Hexoskin connected health platform.(26:48) Talking regulation and FDA.(29:10) Future garments and new tech from HexoskinOur GuestPierre-Alexander Fourier is an entrepreneur, designer, and scientist. He is the co-founder of Hexoskin, the leading sensor and AI/analytics company for health, research, and medicine, founded to improve care for people with chronic and rare diseases.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubePierre-Alexander Fournierhttps://www.linkedin.com/in/pafournier/Hexoskinhttps://www.hexoskin.com/

This week on The Bleeding Edge of Digital Health, host Mike Moore is joined by Jani Tuomi, Digital Health Leader and co-founder of imaware. His company specializes in at-home, patient-administered customized diagnostic tests. Jani lost a loved one due to a misdiagnosis, and his company has a passion and goal for helping people make informed healthcare decisions about critical health conditions such as cardiovascular disease, and autoimmune conditions.Mike and Jani discuss the latest in precision medicine and how imaware is leading the way for providing doctors and patients with the latest, more accurate data and assessment of their health condition as quicky as possible. Listen to their entire discussion as they talk about costs, challenges, competitors, and most importantly how imaware is growing without sacrificing innovation.Notable Quotes“So, when you open this report, it speaks to you as an expert physician would. And I think that really helps patients just understand what they're looking at, understand what these results are relative to where they should be, what they could be improving, and then help map out a plan alongside either virtual care, that we can provide through telemedicine or back to their doctor and help them act on it. We've had a lot of physicians who've had patients take more reports in say, Yeah, I can trust this because I see you have this science, this expert, and I'm going to run with that.” – Jani (10:57)“We're almost at a level of infinite numbers of tests that these patients can get. So, we don't just have 18 tests off the shelf, and we sell everybody the same test. It's the biomarkers you need to give your family history, the condition, and the symptoms you think that you're presenting and the physician's thoughts on it when ordering.” – Jani (21:10)In This Episode(02:20) How did imaware come about?(06:58) The finger prick biomarkers in 2017.(09:23) How is imaware different than its competitors?(13:53) Expanding on the process for patient results and interpretation.(18:47) Expanding on the digital component of the test and its implications.(20:58) How many tests do they offer?(22:16) On building and iterating products quickly.(24:36) The shift from DTC to B2B and B2C.(27:40) How is all this paid for?(32:00) Talking about new, upcoming tech in the future.(36:59) How to focus on growth and innovate at the same time.Our GuestJani Tuomi is a digital health leader and co-founder of imaware, a company specializing in at-home, patient-administered customized diagnostic tests. Jani is passionate about helping people make informed healthcare decisions about health conditions such as cardiovascular diseases and autoimmune conditions from their own homes to engage their doctors as early as possible.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeJani Tuomihttps://www.linkedin.com/in/janituomi/imawarehttps://www.imaware.health/

This week on The Bleeding Edge of Digital Health, host Mike Moore is joined by Patrick Jamnik, president of Episurf Medical Inc,. to talk about joint replacement procedures and the challenges surrounding this crucial surgery. How can we know when it’s the right time to get it done? The line between going in too early or putting it off too long is not so well defined which is a concern for both patients and surgeons. No patient wants to go through joint replacement surgery only to learn they must go through it again a year or so later. Listen as both Mike and Patrick talk about personalized orthopedic implants, 3D image processing, Episurf products, reimbursements, and more importantly how their software is one decisive step toward surgeons and patients making a key surgical decision at the right time.Notable Quotes“We call these damage marking reports. So, a patient will go and get a 3D MRI using a protocol that we designed, and it will produce a couple of different things back for them. So, what our damage marking reports will do is map out the entire sort of cartilage surface and show the surgeon just exactly where the problem spot is and how severe the problem spot is.” – Patrick (16:15)“They don't have the right supportive kind of adjunctive patient selection tool. That's where we see our software capabilities as really providing that supportive function to help in their patient selection journey where they know ahead of time when they go into the surgery.”– Patrick (35:20)In This Episode(01:20) The origins and evolution of Episurf Medical and how he got started.(06:50) The use case of the technology currently on the market for surgeons and patients.(09:46) Expanding on biologics and STEM cell treatment.(14:44) The right time to get a knee replacement.(16:05) Diving into 3D MRI imaging assessment.(22:37) On developing an emotional connection with the patient.(23:11) What procedure does Episurf make implants for?(30:17) Talking about a toe product in development.(32:40) Talking reimbursements and separate codes.(33:50) Other companies doing similar work.(35:56) The digital solution validates the decision for patients.Our GuestPatrick Jamnik is the president of Episurf Medical Inc., a Stockholm-based company that specializes in the treatment of painful joint injuries and is an industry leader in individualized technology. Patrick is passionate about helping surgeons treat the middle-aged "gap patient" who doesn't yet need a joint replacement or fusion.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubePatrick Jamnikhttps://www.linkedin.com/in/pajamnik/Episurfhttps://episurf.com/

This week on The Bleeding Edge of Digital Health, host Mike Moore speaks with Paul Jaure and Jennifer Holmes, Founder and CEO of Rehab Boost, an AI-powered body recognition platform. Join Mike and his guests as they discuss how this tool assists patients in the successful implementation of their rehab treatment plan and how it is revolutionizing the future of rehabilitation powered by Artificial Intelligence.Notable Quotes“We make it much better for their time to be more efficient because with one click you have an entire treatment or program, what we call rehabilitation program with different phases for different weeks. You can go all the way to the next six months with one click. So you have phases one, two, three, all the way through different phases that the patient keeps evolving through the treatment plan. But yeah, all of you know, from an even range of motion, we never envisioned range of motion being a part of the platform as well. So yeah, yeah, we're very proud of that back end as well.” – Paul (21:39)“So virtual home programs and incentivize the therapy community to stand those up so they can serve those communities, especially, again, the rural communities. Right. Because those patients don't come back. I mean, I think we shared with you the data that 70% of patients that start a rehab program don't ever come back, even though they've got authorization from their insurance provider. They just don't finish it.”– Jennifer (12:05)In This Episode(01:35) Paul talks about the story behind Rehab Boost.(04:09) Discussing the use case around this technology.(07:15) On patient commute being a big reason behind Rehab Boost(09:01) Talking about the app-based super easy setup process.(10:54) Paul takes Mike through a demo.(15:34) What the app does when a patient experiences pain.(17:28) Discussing the applications of Rehab Boost outside of MSK.(18:52) Explaining the backend infrastructure and tracking patient progress.(22:57) Jennifer provides some useful statistics for the MSC market.(27:23) Jennifer and Mike talk about reimbursement codes.(29:20) On launching and commercializing Rehab Boost.Our GuestsPaul Jaure is the founder of Rehab Boost. He specializes in leveraging technology to replicate human processes and has successfully created several start-ups based on that ideology. He has an extensive business background in international and multicultural environments and proven achievements in product innovation, distribution, and software development in technological industries.Jennifer Holmes is the CEO of Rehab Boost. She is a visionary, strategic, and results-driven senior executive leader with 30 years of healthcare experience leading US & Global commercial strategy for blue chip, mid-cap, and private equity-backed startup companies. She has extensive experience in strategic and succession planning, launching SaaS technologies, implementing operational plans & digital marketing, and guiding M&A initiatives while building and transforming corporate cultures.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubePaul Jaurehttps://www.linkedin.com/in/pauljaure/Jennifer Holmeshttps://www.linkedin.com/in/jennifervaughanholmes2187513/Rehab Boosthttps://rehabboost.com/

In this week’s episode of The Bleeding Edge of Digital Health, Mike Moore sits down with Bill Hunter, CEO and founder of Canary Medical, to explore the orthopedic implant business and how Canary’s devices are changing the landscape of aftercare and the measurement of patient progress.   Bill discusses the dissatisfaction he observed among patients and how many companies weren’t utilizing a combination of resources to measure recovery, health, mobility, etc. With Persona IQ and the implants Canary has designed, they combine those resources to accurately assess patients by defining patient baselines and milestones before and after surgery. He also shares where he hopes to take this company and the ethical questions he pondered regarding user data and privacy, clinician access, and more. Tune in to this episode to learn more about these tiny but revolutionary products. Notable Quotes“It seemed absurd to me that all this medical hardware went in and none of it reported back. And it turned out that it wasn’t really, much like Angiotech, it wasn’t a technology problem. It’s not like the drugs didn’t exist. It’s not like the sensors didn’t exist or the power sources or transmission technology – it all existed. It’s just that no one had really bothered to put it together… So that was the premise of Canary, and as you alluded to, the canary in the coal mine was the first biological sentinel.” – Bill (4:31)“You do all this planning. You do all this intraoperative planning. Surgeries now are incredibly precise. And then you kind of walk the patient to the front door of the hospital and say, ‘See you in thirty days.’ If you follow that patient journey, more than 50% of people don’t come back for that 30-day visit, so you might not see the patient till three months, six months, whatever. So this whole recovery period, I mean, as we started doing these types of things – ‘What is a normal step count on day five? What is your range of motion on day seven? When do people start climbing stairs?’ A lot of this stuff just flat out wasn’t known… Coming up with the measuring tools was a really important first step.” – Bill (19:12) In This Episode(1:01) Canary Medical’s recent conferences (3:10) How Canary began and how they chose the company’s name (5:53) Bill’s background and the creation of their first few devices (8:25) How Zimmer became a successful partnership(12:28) Why they chose not to design their own implant (14:01) The dissatisfaction that prompted the creation of this implant(18:36) The technical barriers that are resolved by this technology(22:08) Measuring progress and creating a baseline for patients pre-surgery (23:33) How Canary navigates data ownership and privacy concerns(28:50) Breaking down the components of the device (31:37) How this technology is changing the industry on an institutional level (38:27) The current competition for Persona IQ(40:35) Where Bill hopes to take Canary in the future Our GuestBill Hunter is the CEO and founder of Canary Medical. After spending years as a practicing doctor, he noticed a hole in healthcare where many companies failed to utilize various resources together. With Canary Medical, his team is creating new and innovative technology to mark patient health and progress in a more accurate and personalized sense. Resources & LinksMike MooreLinkedInThe Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeLinkedInBill HunterLinkedInCanary Medical Website

In this week’s episode of The Bleeding Edge of Digital Health, Mike Moore chats with medical futurist and keynote speaker Bertalan Mesko to discuss modern medicine's future and the trends impacting the industry. As a professional and seasoned futurist, Bertalan has spent his life studying medicine and pushing the boundaries of what is possible for the healthcare system to bring the industry into a new age. With his commitment to this profession, he is also beginning a program to support the next generation of medical futurists and thought leaders. In their conversation, Bertalan shares his thoughts on the trends he has observed as companies and corporations push forward into the future of digital health. He also touches on the six points he uses to assess a technology’s potential and the pros and cons that come with digital and technological advances on an individual level. Notable Quotes“For the first time in the history of medicine, now patients can sit at the same table that only their physicians have been sitting at since the dawn of modern medicine. I think that simply is the biggest milestone in history, and that is the challenge we should all focus on – to acknowledge the importance of patient empowerment. Because everything, every technological trend, every major change in how we deliver healthcare, how we practice medicine, would come after that. Because this is the change that initiated that whole transformation that we call digital health.” – Bertalan (2:42) “We have to make sure only tested, safe products reach people and get into the lives of patients, so then we can keep them alive and healthy for as long as possible. That’s why healthcare is so unique, and that’s why it’s so important to employ futuristic studies into the mindset of those people that make decisions about the near future of healthcare.” – Bertalan (20:22)In This Episode(2:06) Patient empowerment is the future of modern medicine(9:50) The “Digital Health in a Minute” series(10:58) Why medicine may become telemedicine in years to come(13:16) Why in-person care is not sustainable  (17:02) The importance of medical futuristic studies (20:47) How Bertalan is investing in the next generation of medical futurists(24:17) The 6 qualities Bertalan looks for in emerging medical companies/technologies(29:58) Why a lack of humility limits the success of big corporations  (35:28) The give and take that comes with digital advancement The Six Qualities for Company/Technology Assessment:The technology needs to meet a specific patient or clinical need. . The technology has to be scientifically backed. The technology should share the data with patients as well as physicians. The technology should improve doctor/patient relationships.The technology should be accessible through technology/software/devices that users already own. The technology should help globalize healthcare.   Our GuestDr. Bertalan Mesko, PhD is The Medical Futurist and the Director of The Medical Futurist Institute analyzing how science fiction technologies can become reality in medicine and healthcare. As a geek physician with a PhD in genomics, he is also an Amazon Top 100 author. He is also a Private Professor at Semmelweis Medical School, Budapest, Hungary. With his team at The Medical Futurist, he’s sharing his research with not just medical professionals but the general public as well through projects such as his “Digital Health in a Minute” YouTube series. He is also in the process of building a program to support the next generation of futurists and researchers. Resources & LinksMike MooreLinkedInThe Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeLinkedInBertalan MeskóLinkedInInstagramTwitterYouTubeFacebook

CEO of Digital Salutem, keynote speaker, and thought leader in the healthcare industry João Bocas is joining Mike Moore on this week’s episode to discuss Joao’s skillset, observations about the healthcare industry, and his work as The Wearables Expert™. As they discuss the future of healthcare, obstacles for startups and big tech companies, and why mobile healthcare is dominating the industry, João shares how his 25 years of experience in corporate environments has informed his understanding of the direction the healthcare industry is heading given current technological advancements. He also shares his ultimate vision for the future of care as they unpack the politics that currently exist in the realm of data ownership, production, and analysis. Notable Quotes“This would be my ultimate vision. I would love to see as people, patients if you like, turn the system upside down, and one day the power be transferred not from the organization that owns the data but to the patient. And the patient approaches the organization and says, ‘Here is my data. Help me.’” – João (27:34)In This Episode(2:01) The rate at which the industry evolves and the issue of fragmentation(7:29) How to assess the potential and success of a digital health company(13:39) João’s predictions about future verticals (15:42) mHealth growth in the industry (17:00) The obstacles that exist for big tech companies in digital health(20:42) Accumulating data vs. understanding it(22:50) The challenges that arise when developing insights(24:38) The politics of data ownership Our GuestJoão Bocas is the CEO of Digital Salutem, a digital influencer, keynote speaker, and The Wearables Expert. With over 25 years of corporate experience in various industries including finance, media, sporting, and healthcare, he’s using his expertise in wearable technology to support the rise of digital health and refine the industry as a whole. Resources & LinksMike MooreLinkedInThe Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeLinkedInJoão Bocas TwitterLinkedInYouTube

In this week’s episode, host Mike Moore talks with Will Martin, President & CEO of IRRAS, about a transformative product in the healthcare market.IRRAS’ primary focus is designing and developing innovative solutions to fluid management and drainage after surgical procedures, particularly neurosurgical ones. Their first commercial product, IRRAflow®, helps to manage the drainage of intracranial fluids and prevent blockages from forming.Today, Mike and Will discuss the difference IRRAflow® can make in the practice of neurological medicine, the impact it has on improving patient outcomes, and the challenges IRRAS faces in getting their products into the healthcare system.Notable Quotes“It has just become a treatment situation where these shortcomings are now well accepted, and it’s something that we as a company don’t accept. And we’re looking on a daily basis not only to improve the opportunities for these patients, but then to shift it from that passive approach into a therapeutic one where we’re aggressively trying to get that clot out in a matter of days as opposed to a matter of weeks.” – Will (12:04)In This Episode(1:38) Overview of Will’s career through medical technology startups(03:28) How Will made the decision to transition to IRRAS(07:40) Discussion of the company’s products, specifically IRRAflow®(08:44) Acquisition of Hummingbird ICP Neuromonitoring products(09:45) The problem IRRAflow® solves(12:28) How flushing a neurological catheter works(13:20) Infection as a paramount concern for the health system(15:07) How IRRAflow® works and its impact(17:32) Improving patient outcomes and reducing length of hospital stay(20:12) The digital component of the product(23:02) The biggest challenges IRRAS faces(30:52) IRRAS’ exciting new partnership with MedtronicOur GuestWill Martin is the President & CEO of IRRAS, which he joined in 2018. With a background education in economics, finance, and management, he has extensive experience with marketing and sales of key health technologies. He has served in several key leadership roles across medical technology companies to drive growth, expansion, and bring crucial, new products to market.Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/Will Martin https://www.linkedin.com/in/will-martin-01b3105/https://www.linkedin.com/company/irras-ab/about/http://www.irras.com/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTube

As more technologies emerge to diagnose and treat various physiological and health-related problems, Mike Moore sits down on this week’s episode to chat with Dr. Geoffrey Strange and Deon Strydom of Echo IQ. This revolutionary digital resource works to identify existing heart disease or conditions for future structural heart issues.   With Dr. Strange as Echo IQ’s Chief Research and Strategy Officer and Deon Strydom at the head of the commercial side as Chief Commercial Officer, these two have worked tirelessly together to create and develop a product that can diagnose both efficiently and accurately. Tune in to today’s episode to learn more about how Echo IQ was built, their challenges along the way, their hope for the company's future, and how AI is changing the landscape of cardiovascular health. Notable Quotes“All of those parameters are collected on echocardiography. And because we’ve been able to bring all of that together, we’re able to truly see the multi-dimensional interrelationships in a way that we as humans attempt to do, but this is a uniform process. Happens the same every time. It’s not tired at the end of the day, you know? Equitable access to everybody.” – Dr. Strange (9:36)“One out of eight patients over the age of 65 have some form of structural heart disease, and if you take something like aortic stenosis like Professor Strange mentioned earlier, you have to keep in mind that there’s a 50% two-year survival rate, so you can see that there’s a real need to act really urgently. So that gives a bit of the size of the market.” – Deon (12:18)In This Episode(2:29) The spark behind Echo IQ  (4:35) How Echo IQ was built and how it works(7:55) The software’s unique capabilities(11:52) Deon reveals the size of the market and patient care(19:03) How they acquired the data and how they worked to fit their software into the current market(22:28) Echo IQ’s customers and users in the healthcare industry(29:10) How AI can help patients with aortic stenosis(30:55) Echo IQ’s commercial model for the US (34:05) Dr. Strange and Deon share the challenges that may lie ahead for the companyOur GuestsDr. Geoffrey Strange – Chief Research and Strategy Officer – and Deon Strydom – Chief Commercial Officer – of Echo IQ are currently revolutionizing the way in which different forms of heart disease are diagnosed. As they work to further develop this technology and overcome obstacles related to this disease and the healthcare system as a whole, they are committed to moving into the future of cardiovascular health and treatment. Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeDr. Geoffrey Strange LinkedInDeon StrydomLinkedInEcho IQWebsite

Mike Moore chats with Eko Health founder and CEO Connor Landgraf on this week’s episode to discuss the creation of Eko’s AI-powered stethoscope, a powerful tool that aims to more effectively and efficiently diagnose and treat lung and heart disease. As Connor unpacks the creation of Eko, the history of stethoscopes, and how the software itself is sold, he also reveals how it’s being accepted in the field as a whole and how the FDA views technological leaps in the medical field. While Eko Health, in just six years, has already become a valuable resource among providers, both on an individual and an institutional level, Connor Landgraf also takes some time to share where he hopes to take this technology in the future. Notable Quotes“Getting the sound to be loud enough is a big challenge. Depending upon the patient, their body anatomy, there’s a lot of things. They can also have really diminished heart sounds or breath sounds in certain situations. So literally just hearing the sounds in an ICU, with monitors going on in the background beeping, intubation machines, there's just all these noises that make it really hard for the provider to hear the patient's heart sounds or breath sounds. So even just being able to like isolate and amplify the sound makes a big difference to the provider’s confidence.” - Connor (7:35)“We have indications on the AI side for identifying structural murmurs associated with valvular heart disease, doing arrhythmia assessments, identification of AFib, some basic assessments of heart rate (so bradycardia and tachycardia), and then we have an algorithm in development that lets us do prediction of whether a patient likely has low ejection fraction or an impaired, a weak heart pump, weak heart muscle, and the ability to actually kind of flag that and say, ‘Hey, there’s early signs…’” - Connor (11:12)In This Episode(1:13) Connor Landgraf shares Eko’s beginning (4:23) The issue of misdetection with regular stethoscopes (9:36) Eko’s current capability, development, and tiers of access (15:30) Growth of the digital device since 2016 and the FDA’s perspective(20:23) How the industry is helping the FDA widen their understanding of digital health (22:31) Connor hints at possible future technology from Eko(26:12) Touching on competition in the market Our GuestFounder and CEO of Eko Health Connor Landgraf developed an AI-powered stethoscope, algorithm, and software to help physicians diagnose and treat heart and lung disease in patients more efficiently and effectively. While Eko Health caters to both the individual physician and the institutional market, this digital-centered stethoscope is just the beginning for Eko. Resources & LinksMike Moorehttps://www.linkedin.com/in/michaeljeffreymoore/https://www.linkedin.com/company/thebleedingedgeofdigitalhealth/The Bleeding Edge of Digital HealthApple PodcastsGoogleAmazonSpotifyYouTubeConnor LandgrafLinkedInEko Health